Last reviewed · How we verify
High dose influenza vaccination
High-dose influenza vaccination stimulates a stronger immune response by delivering a higher antigen load to enhance antibody production and cellular immunity against influenza viruses.
High-dose influenza vaccination stimulates a stronger immune response by delivering a higher antigen load to enhance antibody production and cellular immunity against influenza viruses. Used for Prevention of influenza in adults aged 65 years and older, Prevention of influenza in immunocompromised populations.
At a glance
| Generic name | High dose influenza vaccination |
|---|---|
| Also known as | Fluzone high dose quadrivalent |
| Sponsor | University of Miami |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Standard influenza vaccines contain 15 micrograms of hemagglutinin per strain, while high-dose formulations contain 60 micrograms per strain. This increased antigen quantity triggers more robust activation of B cells and T cells, resulting in higher antibody titers and improved protection, particularly in older adults with waning immune function. The enhanced immunogenicity translates to better clinical efficacy in preventing influenza infection and reducing severe outcomes.
Approved indications
- Prevention of influenza in adults aged 65 years and older
- Prevention of influenza in immunocompromised populations
Common side effects
- Injection site soreness
- Myalgia
- Fatigue
- Headache
- Low-grade fever
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe
- A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis (PHASE1)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older (PHASE1, PHASE2)
- Open-Label Influenza Vaccine Evaluation (NA)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High dose influenza vaccination CI brief — competitive landscape report
- High dose influenza vaccination updates RSS · CI watch RSS
- University of Miami portfolio CI